Search

Your search keyword '"Craik CS"' showing total 412 results

Search Constraints

Start Over You searched for: Author "Craik CS" Remove constraint Author: "Craik CS"
412 results on '"Craik CS"'

Search Results

1. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity

2. Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity

3. Cullin E3 ligases and their rewiring by viral factors.

5. Broad-spectrum allosteric inhibition of herpesvirus proteases

6. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance

7. Current and potential treatments for ubiquitous but neglected herpesvirus infections

8. Efficient targeting to storage granules of human proinsulins with altered propeptide domain.

9. The exocrine protein trypsinogen is targeted into the secretory granules of an endocrine cell line: studies by gene transfer.

10. Mutational tail loss is an evolutionary mechanism for liberating marapsins and other type i serine proteases Fromtransmembrane anchors

11. Structure-Function Analyses of Human Kallikrein-related Peptidase 2 Establish the 99-Loop as Master Regulator of Activity

12. Dissecting the Active Site of the Collagenolytic Cathepsin L3 Protease of the Invasive Stage of Fasciola hepatica

13. Structural and functional relationships in the virulence-associated cathepsin L proteases of the parasitic liver fluke, Fasciola hepatica

15. Leucine Aminopeptidase LyLAP enables lysosomal degradation of membrane proteins.

16. Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I complex Demonstrates the Antitumor Efficacy of Hapten-Based Strategies.

17. Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP.

18. Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin.

19. Imaging the Granzyme Mediated Host Immune Response to Viral and Bacterial Pathogens In Vivo Using Positron Emission Tomography.

20. Structural basis of prostaglandin efflux by MRP4.

21. Proteases influence colony aggregation behavior in Vibrio cholerae.

22. Preparing for the next pandemic.

23. Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets.

24. Phosphorylation of a Cleaved Tau Proteoform at a Single Residue Inhibits Binding to the E3 Ubiquitin Ligase, CHIP.

25. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.

26. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors.

27. A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19.

28. Discovery and Characterization of Antibody Probes of Module 2 of the 6-Deoxyerythronolide B Synthase.

29. The E3 Ubiquitin Ligase, CHIP/STUB1, Inhibits Aggregation of Phosphorylated Proteoforms of Microtubule-associated Protein Tau (MAPT).

31. Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.

32. Accurate Identification of Mucinous Pancreatic Cystic Lesions Using Small-Volume Analytes.

33. Addressing the unmet clinical need for low-volume assays in early diagnosis of pancreatic cancer.

34. Multiplex substrate profiling by mass spectrometry for proteases.

35. High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions.

36. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M pro and Papain-like Protease PL pro of SARS-CoV-2.

37. Incidence and Prevalence of Coronavirus Disease 2019 Within a Healthcare Worker Cohort During the First Year of the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic.

38. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy.

39. Structure-function analysis of enterovirus protease 2A in complex with its essential host factor SETD3.

40. Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts.

41. Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine.

42. Design of a population-based longitudinal cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco Bay Area.

43. Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2.

44. Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.

45. Immunotargeting of Nanocrystals by SpyCatcher Conjugation of Engineered Antibodies.

46. End-Binding E3 Ubiquitin Ligases Enable Protease Signaling.

47. Mapping the catalytic conformations of an assembly-line polyketide synthase module.

48. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET.

49. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.

50. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential.

Catalog

Books, media, physical & digital resources